Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 3032-3034

  Pankuch, Glenn A ^a   Hoellman, Dianne B ^a   Lin, Gengrong ^a   Bajaksouzian, Saralee ^b   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; PRISTINAMYCIN; ROXITHROMYCIN;

ANIMAL CELL; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATION; CELL VIABILITY; DRUG DETERMINATION; DRUG EFFECT; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 0031755086     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.3032     Document Type: Article

References (21)

1. Agouridas, C., A. Bonnefoy, and J. F. Chantot. 1997. Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens. Antimicrob. Agents Chemother. 41:2149-2158.
2. Berk, S. L., J. H. Kalbfleisch, and The Alexander Project Collaborative Group. 1996. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in the USA. J. Antimicrob. Chemother. 38(Suppl. A):85-96.
3. Bryskier, A., C. Agouridas, and J. F. Chantot. 1996. Ketolides: new semi-synthetic 14-membered ring macrolides, p. 39-50. In S. H. Zinner, L. S. Young, J. F. Acar, and H. C. Neu (ed.), Expanding indications for the new macrolides, azalides and streptogramins. Marcel Dekker, Inc., New York, N.Y.
4. Felmingham, D., M. J. Robbins, A. Leakey, R. Cooke, C. Dencer, H. Salman, G. L. Ridgway, R. N. Grüneberg, and A. Bryskier. 1997. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates, abstr. F-116, p. 166. American Society for Microbiology, Washington, D.C. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.
5. Goldstein, F. W., M. E. Emiran, A. Coutrot, and J. F. Acar. 1990. Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. J. Antimicrob. Chemother. 25(Suppl. A):25-28.
6. Jamjian, C., D. J. Biedenbach, and R. N. Jones. 1997. In vitro evaluation of a novel ketolide antimicrobial agent, RU 64004. Antimicrob. Agents Chemother. 41:454-459.
7. Jones, R. N., and D. J. Biedenbach. 1997. Antimicrobial activity of RU-66647, A new ketolide. Diagn. Microbiol. Infect. Dis. 27:7-12.
8. Maskell, J. P., A. M. Sefton, and J. D. Williams. 1990. Comparative in-vitro activity of azithromycin and erythromycin against gram-positive cocci, Haemophilus influenzae and anaerobes. J. Antimicrob. Chemother. 25(Suppl A): 19-24.
9. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication no. M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
10. Needham, C. A. 1988. Haemophilus influenzae: antibiotic susceptibility. Clin. Microbiol. Rev. 1:218-227.
11. Neu, H. C. 1991. The development of macrolides: clarithromycin in perspective. J. Antimicrob. Chemother. 27(Suppl. A):1-9.
12. Olsson-Liljequist, B., and B. M. Hoffman. 1991. In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite against Haemophilus influenzae. J. Antimicrob. Chemother. 27(Suppl. A):11-17.
13. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994 Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.
14. Pankuch, G. A., C. Lichtenberger, M. R. Jacobs, and P. C. Appelbaum. 1996. Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob. Agents Chemother. 40:1653-1656.
15. Pankuch, G. A., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1998. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. 42:624-630.
16. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.
17. Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother 41:2251-2255.
18. Vallée, E., A. Azoulay-Dupuis, R. Swanson, E. Bergogne-Bérézin, and J. J. Pocidalo. 1991. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. J. Antimicrob. Chemother. 27(Suppl. A):31-41.
19. Vazifeh, D., H. Abdelghaffar, and M. T. Labro. 1997. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob. Agents Chemother. 41:2099-2107.
20. Wise, R., and J. M. Andrews. 1997. The in vitro activity of the new ketolide HMR 3647 against a wide range of clinical isolates, abstr. F-114, p. 165. American Society for Microbiology, Washington, D.C. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.
21. Yeo, S. F., E. Akalin, S. Arikan, R. Auckenthaler, T. Bergan, K. Dornbusch, A. J. Howard, W. Hryniewicz, R. N. Jones, G. Koupari, N. J. Legakis, J. McLaughlin, C. Ozkuyumcu, A. Percival, I. Phillips, D. Reeves, R. Spencer, R. E. Warren, and J. D. Williams. 1996. Susceptibility testing of Haemophilus influence - an international collaborative study in quality assessment. J. Antimicrob. Chemother. 38:363-386.